NEW YORK (360Dx) — Swedish biopharmaceutical firm BioArctic announced today that it has partnered with Brain Biomarker Solutions (BBS) to develop new biomarkers and diagnostic methods for Alzheimer's disease.

Under the terms of the deal, BioArctic will work with BBS — a spinout of the University of Gothenburg — to identify and measure new blood- and cerebrospinal fluid-based biomarkers that can be used to diagnose Alzheimer's disease and monitor the effects of investigational treatments for the condition.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.